--- title: Why Big Pharma Is Taking a Closer Look at Psychedelic Medicine description: Explore the evolving landscape of psychedelic medicine as Big Pharma invests in diverse therapies, shaping a more selective and promising future for mental health treatments. image: https://insights.advisorshares.com/hubfs/01a06ae5-aa61-75a3-a344-f4fb949e392f_0.jpg --- [Skip to content](https://insights.advisorshares.com/alpha-insights/why-big-pharma-is-taking-a-closer-look-at-psychedelic-medicine#main-content) [![AdvisorShares logo](https://insights.advisorshares.com/hs-fs/hubfs/_AS%20Logos%20-%20Images/as-logo-800x120.jpg?width=400&height=67&name=as-logo-800x120.jpg)](https://advisorshares.com/) Open main navigation Close main navigation [All posts](https://insights.advisorshares.com/alpha-insights/all) September 16, 2026 # Why Big Pharma Is Taking a Closer Look at Psychedelic Medicine ![Picture of AdvisorShares](https://insights.advisorshares.com/hs-fs/hubfs/_AS%20Logos%20-%20Images/AS%20icon2.png?width=50&name=AS%20icon2.png) By  [AdvisorShares](https://insights.advisorshares.com/alpha-insights/author/advisorshares)  ·  8 minute read The investment landscape surrounding psychedelic medicine bears little resemblance to the one that emerged during the sector's first wave of public-market enthusiasm. Early interest brought capital into a wide range of businesses, many of them years away from meaningful clinical or commercial milestones, before tighter financing conditions and longer-than-expected development timelines forced the industry through a difficult reset. That reset narrowed pipelines, pushed companies to conserve capital and contributed to a wave of restructurings, consolidations and changing corporate identities. It also gave the companies that continued developing drugs more time to generate the kind of information that pharmaceutical investors and strategic buyers typically expect: late-stage clinical data, clearer regulatory pathways, more developed intellectual-property portfolios and a better understanding of what treatment might require in practice. The result is a psychedelic investment universe that is beginning to look less like a single emerging theme and more like a collection of individual biotechnology programs. The change has become particularly visible over the past year as AbbVie, Otsuka and Eli Lilly have committed billions of dollars to psychedelic or psychedelic-related assets, while Johnson & Johnson has reportedly moved toward an investment in a company taking the underlying science in another direction entirely.1, 2, 3, 4 **Why Has Pharmaceutical Interest Grown?** Mental-health drug development has long presented both a challenge and an opportunity for the pharmaceutical industry. Depression, PTSD and anxiety disorders affect large patient populations, while existing therapies can require chronic treatment and may not provide adequate relief for every patient. New mechanisms that could broaden the available treatment options have therefore remained an important area of research even as central nervous system drug development has historically carried high clinical risk. Psychedelic developers are now reaching a stage where potential partners can evaluate more than the underlying theory. Psilocybin and LSD programs have produced Phase 3 data, other candidates are entering pivotal studies, and the FDA's final guidance for psychedelic clinical investigations provides a more defined framework for how these programs can be studied.5  Pharmaceutical companies considering the sector can increasingly assess trial results alongside dosing schedules, manufacturing plans, regulatory history, intellectual property and the amount of capital likely to be required before commercialization. The deals that have followed do not all involve the same type of drug, and that variety may be one of the more revealing parts of the story. ![ChatGPT Image Sep 4, 2026, 03\_31\_31 AM](https://insights.advisorshares.com/hs-fs/hubfs/ChatGPT%20Image%20Sep%204%2c%202026%2c%2003_31_31%20AM.png?width=1536&height=1024&name=ChatGPT%20Image%20Sep%204%2c%202026%2c%2003_31_31%20AM.png) **A Series of Deals Begins to Define What Buyers Value** AbbVie made one of the first large moves in August 2025, when it agreed to acquire Gilgamesh Pharmaceuticals' bretisilocin program for up to **$1.2 billion**. Bretisilocin is a serotonergic psychedelic being developed for major depressive disorder, and the transaction was structured around the individual asset rather than the entirety of Gilgamesh. Other programs and employees remained in a separate company while AbbVie acquired the lead candidate, allowing the pharmaceutical company to concentrate its investment on a specific clinical program.1 Otsuka's acquisition of Transcend Therapeutics in March 2026 expanded the picture beyond classic psychedelics. The agreement valued Transcend at up to **$1.225 billion**, including $700 million upfront and an additional $525 million tied to sales milestones, with the company's lead methylone candidate, TSND-201, moving into Phase 3 development for PTSD.2 Methylone is an analog of MDMA, and the treatment program uses four once-weekly administrations followed by continued patient observation, creating a clinical model that differs considerably from some of the single-dose approaches being developed elsewhere in the sector. ![ChatGPT Image Sep 4, 2026, 03\_21\_24 AM](https://insights.advisorshares.com/hs-fs/hubfs/ChatGPT%20Image%20Sep%204%2c%202026%2c%2003_21_24%20AM.png?width=1448&height=1086&name=ChatGPT%20Image%20Sep%204%2c%202026%2c%2003_21_24%20AM.png) Otsuka already had experience in psychiatry and prior exposure to psychedelic research, including an earlier investment in Compass Pathways and its 2023 acquisition of Mindset Pharma. The Transcend transaction therefore fits into a broader CNS strategy in which psychedelic-related compounds sit alongside more traditional psychiatric drug development rather than standing apart as an entirely separate category.2 Eli Lilly's agreement to acquire AtaiBeckley in July brought both a larger transaction and a different treatment profile into the conversation. The deal values the company at approximately **$2.8 billion in upfront cash**, with as much as another $1 billion tied to milestones associated with BPL-003 and VLS-01.3 AtaiBeckley's lead program, BPL-003, is an intranasal formulation of 5-MeO-DMT being advanced into Phase 3 for treatment-resistant depression. The shorter duration associated with 5-MeO-DMT adds a commercial consideration that becomes more relevant as these therapies move closer to potential use in healthcare settings. A treatment requiring many hours of patient monitoring places different demands on clinicians, facilities and reimbursement than one that produces a shorter acute experience, so duration can become part of the broader question of whether a clinically successful drug can also be delivered efficiently. That does not make a shorter treatment inherently more effective or more valuable, but it helps explain why companies are evaluating psychedelic assets on more than their pharmacology alone. The range of approaches widened again in August, when Psychedelic Alpha reported that **Johnson & Johnson was set to lead an $85 million Series C financing for Delix Therapeutics** at a $190 million pre-money valuation.4 Delix is developing neuroplastogens intended to capture some of the neuroplasticity-promoting properties associated with psychedelics without producing the traditional hallucinogenic experience. At the time of Psychedelic Alpha's report, the financing was described through documents reviewed by the publication rather than as a completed acquisition, placing it in a different category from the AbbVie, Otsuka and Lilly transactions. Taken across the group, the transactions suggest that pharmaceutical interest is not settling around one definition of psychedelic medicine. Buyers and investors are looking at classic serotonergic psychedelics, MDMA-related compounds, shorter-duration psychedelics and drugs designed to avoid the psychedelic experience altogether, with each approach carrying a different mix of clinical and commercial considerations. **Capital Is Returning With a More Selective Filter** Strategic transactions have coincided with a broader improvement in financing conditions for some psychedelic developers. Psychedelic Alpha recorded **just over $1 billion of financing across ten events during the second quarter of 2026**, the largest quarterly total in the more than six years covered by its financing tracker.6 Most of that money did not spread evenly across the industry. Approximately **$805 million** came from a single Definium Therapeutics financing completed after the company's positive Phase 3 LSD readout, while GH Research raised $117.5 million and Helus Pharma completed a $50 million financing.6 The concentration provides a different perspective on the headline number: capital has become more available, but the largest pools of funding are gathering around companies with advanced clinical programs and identifiable milestones. ![ChatGPT Image Sep 4, 2026, 03\_12\_22 AM](https://insights.advisorshares.com/hs-fs/hubfs/ChatGPT%20Image%20Sep%204%2c%202026%2c%2003_12_22%20AM.png?width=1774&height=887&name=ChatGPT%20Image%20Sep%204%2c%202026%2c%2003_12_22%20AM.png) That distinction matters in drug development because clinical progress and financial durability are closely linked. Phase 3 trials, manufacturing work and regulatory submissions can require substantial investment long before a product generates revenue, leaving companies dependent on their ability to finance each successive stage. A stronger clinical result may therefore do more than increase investor interest in a molecule; it can also improve a developer's ability to fund the work required to reach the next milestone. The environment looks different from the industry's earlier period, when enthusiasm for psychedelics itself could draw capital toward a much broader group of companies. As the sector matures, the ability to distinguish between programs becomes increasingly important. **“Psychedelic” Is Becoming a Broader Investment Category** The companies now grouped within psychedelic medicine cover a widening range of science and business models. Psilocybin and LSD represent classic serotonergic psychedelics, while 5-MeO-DMT and DMT offer shorter-duration experiences that may create different treatment settings. MDMA and methylone are generally classified as entactogens rather than classic psychedelics, although both have become part of the larger psychedelic-therapeutics landscape. Neuroplastogen developers such as Delix are exploring whether some of the biological effects associated with psychedelics can be separated from the subjective experience entirely.4 Those differences affect more than terminology. A drug that requires a full day of clinical monitoring has a different potential cost structure from a shorter-duration treatment, just as a medicine designed for routine prescribing would require a different delivery system from one administered only in specialized treatment centers. Clinical efficacy will ultimately determine whether any of these approaches succeeds, but treatment duration, staffing requirements, intellectual property, reimbursement and manufacturing can shape their commercial prospects alongside the trial data. The sector is therefore beginning to resemble biotechnology more broadly, where one company's success does not validate every company pursuing a related mechanism and one unsuccessful study does not necessarily invalidate the entire field. Company-specific factors become more influential as individual programs move through clinical development. **How Has PSIL Participated in the Change?** The shift in the industry's clinical and capital-markets backdrop has occurred alongside a substantial rebound in psychedelic-related equities. As of August 31, 2026, the **AdvisorShares Psychedelics ETF (PSIL)** had returned **43.43% (NAV) year-to-date** and **59.90% (NAV) over the trailing one-year period**, compared with 13.14% and 20.38%, respectively, for the S&P 500 Index. The longer-term record looks quite different, with PSIL returning **-22.25% annualized since its September 15, 2021 inception** through the same period, illustrating the magnitude of both the recent recovery and the volatility that has accompanied the industry's development. | **Period as of 8/31/2026** | **PSIL NAV** | **PSIL Market Price** | **S&P 500 Index** | | --- | --- | --- | --- | | **1 Month** | 6.16% | 5.12% | 2.72% | | **3 Months** | 14.75% | 13.87% | 1.68% | | **Year-to-Date** | 43.43% | 43.06% | 13.14% | | **1 Year** | 59.90% | 58.68% | 20.38% | | **3 Years (Annualized)** | 19.70% | 16.34% | 21.04% | | **Since Inception (Annualized)** | -22.25% | -22.32% | 13.10% | *Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than original cost. Returns less than one year are not annualized. The S&P 500 Index is a broad-based, unmanaged index and cannot be invested in directly. For standard performance click here: [PSIL.AdvisorShares.com](https://advisorshares.com/etfs/psil/#performance)* Recent performance cannot be attributed to any individual clinical result, acquisition or regulatory development, although the period has coincided with a broader increase in measurable industry catalysts. Investors now have Phase 3 readouts, financing events, pharmaceutical transactions and approaching regulatory submissions to consider alongside the longer-term scientific potential of the field. PSIL's actively managed structure allows its portfolio to change as that opportunity set evolves, which becomes relevant in a market where individual clinical programs can diverge quickly in response to trial results, regulatory decisions, financing needs or corporate transactions. Active management cannot remove those risks, but it provides the flexibility to evaluate companies as their clinical and financial circumstances change. AdvisorShares Psychedelics ETF (PSIL) Top 10 Holdings  | **Stock Ticker** | **Security Description** | **Portfolio Weight** | | --- | --- | --- | | ATAI | ATAIBECKLEY INC | 11.70% | | CMPS | COMPASS PATHWAYS PLC | 10.94% | | DFTX | DEFINIUM THERAPEUTICS, INC | 10.29% | | HELP | CYBIN INC | 7.83% | | ANRO | ALTO NEUROSCIENCE INC | 4.89% | | NRXP | NRX PHARMACEUTICALS INC | 4.66% | | NBIX | NEUROCRINE BIOSCIENCES INC | 4.57% | | GHRS | GH RESEARCH PLC | 4.55% | | RLMD | RELMADA THERAPEUTICS INC | 4.43% | | STIM | NEURONETICS INC | 4.40% | *\*As of 9/03/2026. Holdings and allocations are subject to risks and to change. For the Fund's current holdings click here: [PSIL.AdvisorShares.com](https://advisorshares.com/etfs/psil/#holdings)* **From a Theme to a More Selective Investment Landscape** The first phase of psychedelic investing was shaped heavily by the question of whether the field would develop enough scientific, regulatory and cultural acceptance to become a meaningful healthcare category. That question has not disappeared, although it now sits alongside a more detailed set of considerations. Clinical-stage companies are moving through increasingly different trajectories. Some have reached Phase 3 and attracted large pharmaceutical buyers or new financing, while others remain earlier in development or face greater funding needs. Treatment models are also beginning to diverge as developers explore everything from classic psychedelics to shorter-duration compounds and non-hallucinogenic approaches. The recent involvement of large pharmaceutical companies offers another source of information about how those differences are being valued. AbbVie, Otsuka, Lilly and J&J have not simply invested in “psychedelics” as a broad theme; their activity has centered on individual molecules, clinical programs and treatment characteristics that fit different strategic objectives. As more data arrive, the investment story may continue moving in that direction, with greater emphasis on which companies can finance development, produce convincing clinical results, navigate regulatory review and eventually build treatments that can function within the healthcare system. For investors following the space, that may make the next chapter of psychedelic medicine less uniform than the first—and considerably more dependent on company selection. *Sources:*  1. *Psychedelic Alpha. AbbVie to Acquire Gilgamesh's Bretisilocin for Up to $1.2B. 2025 Aug 25.* 2. *Psychedelic Alpha. Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal. 2026 Mar 27.* 3. *Psychedelic Alpha. Eli Lilly Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 Billion. 2026 Jul 16.* 4. *Psychedelic Alpha. Johnson & Johnson to Lead Delix Therapeutics' $85M Series C. 2026 Aug 18.* 5. *U.S. Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations. Final Guidance. 2026 Jul.* 6. *Psychedelic Alpha. Psychedelic Funding Update: Q2 2026. 2026 Jul 24.* --- | *— **For Institutional Investor Use Only. Not for Public Distribution** —* | | --- | | ***Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus and summary prospectus, a copy of which may be obtained by visiting the Fund’s website at www.AdvisorShares.com. Please read the prospectus carefully before you invest.** Foreside Fund Services, LLC, distributor.* *An investment in the Funds is subject to risk, including the possible loss of principal amount invested. The risks associated with each Fund include the risks associated with the underlying ETFs, which can result in higher volatility, and are detailed in each Fund’s prospectus and on each Fund’s webpage.* *For the Fund's current holdings click here: [PSIL.AdvisorShares.com](https://advisorshares.com/etfs/psil/#holdings)* *AIL-994702-2026-09-01* | [Share this page on Facebook](https://twitter.com/intent/tweet?url=https://insights.advisorshares.com/alpha-insights/why-big-pharma-is-taking-a-closer-look-at-psychedelic-medicine) ## Related posts [![](https://insights.advisorshares.com/hubfs/image%20(7).jpg)](https://insights.advisorshares.com/alpha-insights/psychedelic-medicine-now-has-a-calendar) [PSIL](https://insights.advisorshares.com/alpha-insights/tag/psil) ### [Psychedelic Medicine Now Has a Calendar](https://insights.advisorshares.com/alpha-insights/psychedelic-medicine-now-has-a-calendar) [![](https://insights.advisorshares.com/hubfs/ChatGPT%20Image%20Aug%2021%2c%202026%2c%2012_32_11%20AM.png)](https://insights.advisorshares.com/alpha-insights/draft-when-market-leadership-shifts-a-look-inside-dwus) [DWUS](https://insights.advisorshares.com/alpha-insights/tag/dwus) ### [When Market Leadership Shifts: A Look Inside DWUS](https://insights.advisorshares.com/alpha-insights/draft-when-market-leadership-shifts-a-look-inside-dwus) [![](https://insights.advisorshares.com/hubfs/019f1004-5bf8-7270-93c0-830686766310_0.jpg)](https://insights.advisorshares.com/alpha-insights/qpx-reclassified-what-the-shift-to-tactical-allocation-means) [QPX](https://insights.advisorshares.com/alpha-insights/tag/qpx) ### [Triple 5-Star: QPX's Morningstar Ratings](https://insights.advisorshares.com/alpha-insights/qpx-reclassified-what-the-shift-to-tactical-allocation-means) --- [![AdvisorShares logo](https://insights.advisorshares.com/hs-fs/hubfs/_AS%20Logos%20-%20Images/as-logo-800x120.jpg?width=400&height=67&name=as-logo-800x120.jpg "AdvisorShares logo")](https://advisorshares.com) [Follow us on LinkedIn](https://www.linkedin.com/company/advisorshares/) [Follow us on X](https://x.com/AdvisorShares) [Follow us on Instagram](https://www.instagram.com/advisorshares/) [Follow us on YouTube](https://www.youtube.com/@AdvisorShares) AdvisorShares Investments, LLC 4800 Montgomery Lane Bethesda, Maryland 20814 1.877.843.3831 [Home](https://advisorshares.com/) [About](https://advisorshares.com/about/) [ETFs](https://advisorshares.com/etfs/) [Events](https://advisorshares.com/events/) [Contact Us](https://advisorshares.com/contact-us/) [Privacy](https://advisorshares.com/privacy-policy/)  |  Copyright © 2026, AdvisorShares Investments  |  Foreside Fund Services, LLC, distributor ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "AdvisorShares", "url" : "https://insights.advisorshares.com/alpha-insights/author/advisorshares" }, "dateModified" : "2026-09-16T02:25:53.256Z", "datePublished" : "2026-09-09T12:15:10.000Z", "headline" : "Why Big Pharma Is Taking a Closer Look at Psychedelic Medicine", "image" : [ "https://insights.advisorshares.com/hubfs/01a06ae5-aa61-75a3-a344-f4fb949e392f_0.jpg" ], "mainEntityOfPage" : { "@id" : "https://insights.advisorshares.com/alpha-insights/why-big-pharma-is-taking-a-closer-look-at-psychedelic-medicine", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://insights.advisorshares.com/hubfs/_AS%20Logos%20-%20Images/as-logo-800x120.jpg" }, "name" : "AdvisorShares" } } ``` ```json { "@context" : "http://schema.org", "@type" : "Article", "author" : { "@type" : "Person", "name" : [ "AdvisorShares" ], "url" : "https://insights.advisorshares.com/alpha-insights/author/advisorshares" }, "datePublished" : "2026-09-09T12:15:10+0000", "description" : "Explore the evolving landscape of psychedelic medicine as Big Pharma invests in diverse therapies, shaping a more selective and promising future for mental health treatments.", "headline" : "Why Big Pharma Is Taking a Closer Look at Psychedelic Medicine", "image" : "https://46537736.fs1.hubspotusercontent-na1.net/hubfs/46537736/01a06ae5-aa61-75a3-a344-f4fb949e392f_0.jpg", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://46537736.fs1.hubspotusercontent-na1.net/hubfs/46537736/_AS%20Logos%20-%20Images/as-logo-800x120.jpg" }, "name" : "AdvisorShares Investments" }, "url" : "https://insights.advisorshares.com/alpha-insights/why-big-pharma-is-taking-a-closer-look-at-psychedelic-medicine" } ```